MDT-AP-0229
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 3.96
- os_event
- true
- age_years
- 4
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.052916507
- umap2_2d
- -0.438775493
- umap1_3d
- -0.265619384
- umap2_3d
- -3.459729319
- umap3_3d
- -0.173444316
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.743 |
| 2 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.727 |
| 3 | MDT-AP-2391 | Med | Medulloblastoma | 0.723 |
| 4 | 7b98348a-13f8-404a-9a1e-280ae481b6b0 | — | — | 0.718 |
| 5 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.698 |
| 6 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.690 |
| 7 | SRR12202431 | — | — | 0.686 |
| 8 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.677 |
| 9 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.669 |
| 10 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.659 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |